|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
3.83/-4.43
|
企业价值
22.09B
|
资产负债 |
每股账面净值
89.25
|
现金流量 |
现金流量率
0.28
|
损益表 |
收益
17.31B
|
每股收益
29.07
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/08 22:10 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceuticalcompanies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product. |